UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 100

Sortiert nach

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical genitourinary cancer, 2016-12, Vol.14 (6), p.499-503

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

World journal of urology, 2016-11, Vol.34 (11), p.1567-1573

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Clinical cancer research, 2006-01, Vol.12 (2), p.523-528

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Clinical cancer research, 2005-05, Vol.11 (9), p.3335-3341

2005

Link zum Volltext

Verfügbarkeit prüfen

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer

Cancer control, 2013-01, Vol.20 (1), p.7-16

2013

Link zum Volltext

Verfügbarkeit prüfen

Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma

Cancer control, 2010-10, Vol.17 (4), p.269-278

2010

Link zum Volltext

Verfügbarkeit prüfen

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma

Canadian journal of urology, 2015-08, Vol.22 (4), p.7882

2015

Link zum Volltext

Verfügbarkeit prüfen

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5041-5041

2019

Link zum Volltext

Verfügbarkeit prüfen

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

Expert opinion on pharmacotherapy, 2007-12, Vol.8 (17), p.2979-2990

2007

Link zum Volltext

Verfügbarkeit prüfen

Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.312-312

2019

Link zum Volltext

Verfügbarkeit prüfen

Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4564-4564

2023

Link zum Volltext

Verfügbarkeit prüfen

High-dose bolus interleukin-2: Correlating response rate with number of doses received

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.452-452

2013

Link zum Volltext

Verfügbarkeit prüfen

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5080-5080

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.685-685

2020

Link zum Volltext

Verfügbarkeit prüfen

Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4553-4553

2016

Link zum Volltext

Verfügbarkeit prüfen

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2649-TPS2649

2019

Link zum Volltext

Verfügbarkeit prüfen

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.388-388

2019

Link zum Volltext

Verfügbarkeit prüfen

Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.657-657

2019

Link zum Volltext

Verfügbarkeit prüfen

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.142-142

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.579-579

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I/Ib study of enzalutamide and gemcitabine and cisplatin in bladder cancer

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.338-338

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2632: Increased recurrence and clinical grade in renal cell carcinomas associated with novel EGFR splice variants

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2632-2632

2019

Link zum Volltext

Verfügbarkeit prüfen

Cell-based immune therapy for metastatic renal cancer

Expert review of anticancer therapy, 2003-12, Vol.3 (6), p.837-849

2003

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3111-TPS3111

2017

Link zum Volltext

Verfügbarkeit prüfen

26 – 50 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(98)
Buchkapitel
(2)

Sprache

Englisch
(100)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Humans
(39)
Oncology
(29)
Male
(28)
Aged
(21)
Middle Aged
(20)
Female
(18)
Adult
(14)
Renal Cell Carcinoma
(14)
Treatment Outcome
(13)
Carcinoma, Renal Cell - Drug Therapy
(12)
Kidney Cancer
(12)
Kidney Neoplasms - Drug Therapy
(12)
Kidney Neoplasms - Pathology
(12)
Neoplasm Staging
(11)
Cancer
(10)
Immunotherapy
(10)
Aged, 80 And Over
(9)
Carcinoma, Renal Cell - Pathology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer

Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621)

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer

Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC)

High-dose bolus interleukin-2: Correlating response rate with number of doses received

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)

Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02

Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC)

Phase I/Ib study of enzalutamide and gemcitabine and cisplatin in bladder cancer

Abstract 2632: Increased recurrence and clinical grade in renal cell carcinomas associated with novel EGFR splice variants

Cell-based immune therapy for metastatic renal cancer

A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors

Suchergebnisse filtern